Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Derived from musculoskeletal system – other than cardiac muscle
Reexamination Certificate
2005-02-15
2005-02-15
Witz, Jean C. (Department: 1651)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Derived from musculoskeletal system, other than cardiac muscle
Reexamination Certificate
active
06855338
ABSTRACT:
This invention described a novel use for cartilage extract, namely a shark cartilage extract, in a combined anti-tumor therapy. The cartilage extract is used in combination with anti-neoplastics. The combined therapy provides for a higher anti-tumor efficacy with no concomitant increase, even better with a decrease, of toxic side effects.
REFERENCES:
patent: 3478146 (1969-11-01), Balassa
patent: RE28093 (1974-07-01), Balassa
patent: 3966908 (1976-06-01), Balassa
patent: 4042457 (1977-08-01), Kuettner et al.
patent: 4212857 (1980-07-01), Balassa et al.
patent: 4243582 (1981-01-01), Spilburg et al.
patent: 4350682 (1982-09-01), Balassa
patent: 4356261 (1982-10-01), Kuettner
patent: 4444752 (1984-04-01), Prudden
patent: 4456589 (1984-06-01), Holman et al.
patent: 4469676 (1984-09-01), Hecmati
patent: 4473551 (1984-09-01), Schinitsky
patent: 4656137 (1987-04-01), Balassa
patent: 4746729 (1988-05-01), Kuettner et al.
patent: 4749522 (1988-06-01), Kamarei
patent: 4822607 (1989-04-01), Balassa et al.
patent: 5075112 (1991-12-01), Lane
patent: 5096892 (1992-03-01), Folkman et al.
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5583153 (1996-12-01), Brahn
patent: 5618925 (1997-04-01), Dupont et al.
patent: 5843920 (1998-12-01), Weisz
patent: 5985839 (1999-11-01), Dupont et al.
patent: 6025334 (2000-02-01), Dupont et al.
patent: 6028118 (2000-02-01), Dupont et al.
patent: 6168807 (2001-01-01), Dupont et al.
patent: 45-001444 (1970-01-01), None
patent: 59-039828 (1984-03-01), None
patent: 60-178820 (1985-09-01), None
patent: 9309766 (1993-05-01), None
patent: 9412510 (1994-06-01), None
patent: 9503036 (1995-02-01), None
patent: 9532722 (1995-12-01), None
patent: 9623512 (1996-08-01), None
patent: 9716197 (1997-05-01), None
Oikawa, T., et al., “A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis.”Cancer Letters,51 (1990) 181-186.*
Moses, M., et al., “Inhibitors of Angiogenesis,”Biotech1991; 9; pp. 630-634.*
Folkman, J., et al., “Angiogenic Factors,”Science,vol. 235, pp. 442-446.*
Luer, C.A., “Inhibitors of Angiogenesis from Shark Cartilage,” Fed. Proc. 45(4):949.*
Suzuki, et al., “Cartilage-derived Antitumor Factor (CATF): A High Molecular Weight Fraction Cartilage Extract Inhibits Solid Tumor Growth,”Journal of Bone and Mineral Metabolism,1984 vol. 2, No. 3, pp. 53-57.
Langer, R., et al., “Isolation of a Cartilage Factor That Inhibits Tumor Neovascularization,”Science,vol. 193, pp. 70-72.
Sorgente, N., et al., “The Resistance of Certain Tissues to Invasion,”Laboratory Investigation,vol. 32, No. 2, 1975, pp. 217-222.
Brem, H., et al., “Inhibition of Tumor Angiogenesis Mediated by Cartilage,”The Journal of Experimental Medicine,vol. 141, 1975, pp. 427-439.
Kuettner, K., et al., “Tumor Cell Collagenase and Its Inhibition by a Cartilage-Derived Protease Inhibitor,”Science,vol. 196, pp. 653-654.
Weingarten, M., et al., “Synthetic Substrates of Vertebrate Collagenase,”Biochemistry24, 6730-6734 (1985).
Sadove, A., et al., “Inhibition of Mammary Carcinoma Invasiveness with Cartilage-Derived Inhibitor,”Orthopaedic Surgery,pp. 499-501.
Paull, B., et al., “Regulation of Tumor Invasion by Cartilage-Derived Anti-Invasion Factor in Vitro,”JNCI,vol. 67, No. 1, pp. 65-73 (1981).
Morales, T., et al., “Characterization of the Metalloproteinase Inhibitor Produced by Bovine Articular Chondrocyte Cultures,”Biochimic et Biophysica Acta,760, pp. 221-229 (1983).
Moses, M., et al., “Identification of an Inhibitor of Neovascularization from Cartilage,”Science,vol. 248, pp. 1408-1410.
Moses, M., et al., “A Metalloproteinase Inhibitor as an Inhibitor of Neovascularization,”Journal of Cellular Biochemistry,vol. 47, pp. 230-235 (1991).
Moses, M., “A Cartilage-Derived Inhibitor of Neovascularization and Metalloproteinases,”Clinical and Experimental Rheumatology 11(Suppl. 8), pp. S67-S69 (1993).
Moses, M., et al., “Metalloproteinase Inhibition as a Mechanism for the Inhibition of Angiogenesis,”: Key Principles-Science-Technology-Medicine,pp. 146-151 (1992).
McGuire, T., et al., “Antiproliferative Activity of Shark Cartilage With and Without Tumor Necrosis Factor-α in Human Umbilica Vein Endothelium,”Pharmacotherapy,1996; 16(2), p. 237.
Lee, A., et al., “Shark Cartilage Contains Inhibitors of Tumor Angiogenesis,”Science,vol. 221, pp. 1186-1187.
Medina, “Mammary Tumorigenesis in Chemical Carcinogen-Treated Mice. VI. Tumor-Producing Capabilities of Mammary Dysplasias in BALB/cCrgl Mice,”J. Natl. Cancer Inst.,vol. 57, No. 5, pp. 1185-1189.
Davis, P., et al., “Inhibition of Angiogenesis by Oral Ingestion of Powdered Shark Cartilage in a Rat Model,”Microvascular Research,vol. 54, pp. 178-182 (1997).
Mathews, J., “Media Feeds Frenzy Over Shark Cartilage as Cancer Treatment,”Journal of the National Cancer Institute,vol. 85, No. 15, p. 1190 (1993).
Scott, et al., “Selective Demineralization of Hard Tissues in Organic Solvents: Retention or Extraction of Proteoglycan?”, J. Microsc., 134(3), pp. 291-291.
Pavia et al.,“Introduction to Organic Laboratory Techniques a Contemporary Approach,” 2nd Ed., Saunders College Publishing, Philadelphia, pp. 500-501.
Burdick, et al., “High Purity Solvent Guide,” 2nd Ed., Burdick & Johnson Laboratories, Inc., pp. 128-137.
Sheu, et al., “Effect of U-995, a Potent Shark Cartilage-Derived Angiogenesis Inhibitor, an Anti-Angiogenesis and Anti-Tumor Activities,” Abtucabcer Researcg, 18L, 4435-4442 (1998).
Arnett, F., et al., Arthritis & Rheumatism, 31(3):315-324 (1988).
Chabot-Fletcher, M., et al., “Interleukin-8 Production is Required by Protein Kinase C in Human Keratinocytes,”The Journal of Investigative Dermatology,103(4): 509-515 (1994).
Elias, P.M., “Epidermal Lipids, Barrier Fnction, and Desquamation,”J. Invest. Dermatol.80:044s-049s (1993).
Grove, G.L., “Age-Related Differences in Healing of Superficial Skin Wounds in Humans” inThe effects of aging in oral mucosa and skin.ed. Squier & Hill CRC Press, pp. 121-127.
Matsui, M.S., et al., “Protein Kinase C in Normal Human Epidermal Keratinocytes During Proliferation and Calcium-Induced Differentiation,”J. Invest. Dermatol.99:565-571 (1992).
Medina, D., et al., “Response of Hyperplastic Aveolar Nodule Outgrowth-Line D1 to Mammary Tumor Virus, Nodule-Inducing Virus, and Prolonged . . . ”,J. Natl. Cancer Inst.42:303-310 (1969).
Nickoloff, B.J., et al., “Aberrant Production of Interleukin-8 and Trombospondin-1 Psoriastic Keratinocytes Mediates Angiogenesis,”Am. J. Pathology144(4):820-828 (1994).
Oresajo, C., et al., “Eye Area Problems Puffiness, Bags, Dark Circles and Crowsfeet,”Cosmetics and Toiletries102:29-34 (1987).
Pinnagoda, “Guidelines for transepidermal water loss (TEWL) measurement,”Contact Dermatitis22:164-178 (1990).
Ritchie, et al., “Clinical Studies with an Articular Index for the Assessment of Joint Tenderness in Patients with Rheumatoid Arthritis,”Quarterly Journal of Medicine, New Series XXXVII,No. 147, pp. 393-407 (1968).
Blood, C. H., et al., “Tumor interactions with the vasculature: angiogenesis and tumor metastasis,”Biochimica et Biophysica Acta,1032:89-118 (1990).
Brem, S., “Angiogenesis and Cancer Control: From Concept to Therapeutic Trial,”JMCC,6(5):436-458 (1999).
Davis-Smyth, T., et al., “The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade,”The EMBO Journal15:18, 4919-4927 (1996).
Dupont, E., et al., “Antiangiogenic Properties of a Novel Shark Cartilage Extract:
Brown Randall C.
Haynes and Boone L.L.P.
Les Laboratoires Aeterna Inc.
Witz Jean C.
LandOfFree
Anti-tumor therapies comprising a combination of a cartilage... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-tumor therapies comprising a combination of a cartilage..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tumor therapies comprising a combination of a cartilage... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3504668